ACHN-975

Also Known As:

Benzamide, N-((1S)-2-amino-1-((hydroxyamino)carbonyl)-2-methylpropyl)-4-(4-((1R,2R)-2-(hydroxymethyl)cyclopropyl)-1,3-butadiyn-1-yl)-; N-((2S)-3-Amino-1-(hydroxyamino)-3-methyl-1-oxo-2-butanyl)-4-(4-((1R,2R)-2-(hydroxymethyl)cyclopropyl)-1,3-butadiyn-1-yl)benzamide

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Fan, Shuai: 1 article (03/2021)
2.	Feng, Xiao: 1 article (03/2021)
3.	Jin, Yuanyuan: 1 article (03/2021)
4.	Li, Danyang: 1 article (03/2021)
5.	Lv, Guangxin: 1 article (03/2021)
6.	Wang, Yucheng: 1 article (03/2021)
7.	Wu, Guangteng: 1 article (03/2021)
8.	Yan, Maocai: 1 article (03/2021)
9.	Yang, Zhaoyong: 1 article (03/2021)
10.	Aggen, James B: 1 article (01/2019)

Related Diseases

1.	Communicable Diseases (Infectious Diseases) 03/07/2021 - "The ACHN-975 molecule has high enzymatic inhibitory capacity against the infectious diseases, which are caused by multidrug-resistant bacteria, but clinical research was halted because of its inflammatory response in previous studies. "
2.	Tachycardia (Tachyarrhythmias) 01/01/2019 - "ACHN-975 (N-((S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(((1R,2R)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide) was the first LpxC inhibitor to reach human clinical testing and was discovered to have a dose-limiting cardiovascular toxicity of transient hypotension without compensatory tachycardia. "
3.	Hypotension (Low Blood Pressure) 01/01/2019 - "ACHN-975 (N-((S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(((1R,2R)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide) was the first LpxC inhibitor to reach human clinical testing and was discovered to have a dose-limiting cardiovascular toxicity of transient hypotension without compensatory tachycardia. "